Conditions:  Platinum-resistant Ovarian Cancer;  Fallopian Tube Cancer;  Epithelial Ovarian Cancer;  Ovarian Cancer;  Platinum-Resistant Fallopian Tube Carcinoma;  Platinum-Resistant Primary Peritoneal Carcinoma;  Primary Peritoneal Carcinoma
Interventions:  Drug: Pegylated Liposomal Doxorubicin + SL-172154;  Drug: Mirvetuximab + SL-172154
Sponsor:  Shattuck Labs, Inc.
**RECRUITING NOW**
Interventions:  Drug: Pegylated Liposomal Doxorubicin + SL-172154;  Drug: Mirvetuximab + SL-172154
Sponsor:  Shattuck Labs, Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
